<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ophthalmology</journal-id><journal-title-group><journal-title xml:lang="ru">Офтальмология</journal-title><trans-title-group xml:lang="en"><trans-title>Ophthalmology in Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1816-5095</issn><issn pub-type="epub">2500-0845</issn><publisher><publisher-name>Ophthalmology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18008/1816-5095-2025-1-136-142</article-id><article-id custom-type="elpub" pub-id-type="custom">ophthalmology-2589</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Изучение роли персонализированных факторов риска неудовлетворительного ответа на ангиостатическую терапию на основе регрессионных моделей заболевания</article-title><trans-title-group xml:lang="en"><trans-title>To Study the Role of Personalized Risk Factors for Poor Response to Angiostatic Therapy Based on Regression Models of the Disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3175-9592</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лихванцева</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Likhvantseva</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лихванцева Вера Геннадьевна, доктор медицинских наук, консультант клинико-диагностического центра офтальмологии; профессор кафедры офтальмологии</p><p>ул. Гамалеи, 15, Москва, 123098</p><p>Волоколамское шоссе, 91, Москва, 125310</p></bio><bio xml:lang="en"><p>Likhvantseva Vera G., МD, consultant of the Сlinical and diagnostic center of ophthalmology, Professor of the Ophthalmology Department</p><p>15 Gamalei str., Moscow, 123098</p><p>Volokolamskoe highway, 91, Moscow, 125310</p><p> </p></bio><email xlink:type="simple">likhvantseva-4@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Капкова</surname><given-names>С. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Kapkova</surname><given-names>S. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Капкова Cветлана Георгиевна, заведующая офтальмологическим отделением; доцент кафедры офтальмологии</p><p>ул. Гамалеи, 15, Москва, 123098</p><p>Волоколамское шоссе, 91, Москва, 125310</p><p>ул. Гамалеи, 15, Москва, 123098</p></bio><bio xml:lang="en"><p>Kapkova Svetlana G., Head of the Ophthalmology Department, PhD, Assistant Professor of the Ophthalmology Department</p><p>15 Gamalei str., Moscow, 123098</p><p>Volokolamskoe highway, 91, Moscow, 125310</p><p>15 Gamalei Str., Moscow, 123098</p><p> </p><p> </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Третьяк</surname><given-names>Е. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Tretyak</surname><given-names>E. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Третьяк Евгения Борисовна, кандидат медицинских наук, офтальмолог</p><p>ул. Гамалеи, 15, Москва, 123098</p></bio><bio xml:lang="en"><p>Tretyak Evgeniya B., PhD, ophthalmologist</p><p>15 Gamalei str., Moscow, 123098</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Наумова</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Naumova</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наумова Виктория Игоревна, врач-офтальмолог отделения офтальмологии</p><p>ул. Гамалеи, 15, Москва, 123098</p></bio><bio xml:lang="en"><p>Naumova Victoria I., ophthalmologist, Department of Ophthalmology</p><p>15 Gamalei str., Moscow, 123098</p><p> </p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Плиева</surname><given-names>Х. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Plieva</surname><given-names>H. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Плиева Хава Магамедовна, ассистент кафедры глазных болезней, врач-офтальмолог</p><p>ул. Гамалеи, 15, Москва, 123098</p></bio><bio xml:lang="en"><p>Plieva Khava M., assistant at the Department of Eye Diseases, Ophthalmologist</p><p>Volokolamskoe highway, 91, Moscow, 125310</p><p>15 Gamalei str., Moscow, 123098</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Борисенко</surname><given-names>Т. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Borisenko</surname><given-names>T. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Борисенко Татьяна Евгеньевна, статистик</p><p>ул. Россолимо, 11а, б, Москва 119021</p></bio><bio xml:lang="en"><p>Borisenko Tatyana Е., statistician</p><p>Rossolimo str., 11A, B, Moscow 119021</p></bio><xref ref-type="aff" rid="aff-5"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ ГНЦ «Федеральный медицинский биофизический центр им. А.И. Бурназяна» Федерального медико-биологического агентства; Академия постдипломного образования ФГБУ «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий» Федерального медико-биологического агентства</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.I. Burnasyan Federal Medical Biophysical Center of the Federal Medical Biological Agency; Academy of Postgraduate Education of the Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of Federal Medical Biological Agency</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ ГНЦ «Федеральный медицинский биофизический центр им. А.И. Бурназяна» Федерального медико-биологического агентства; Академия постдипломного образования ФГБУ «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий» Федерального медико-биологического агентства; Медико-биологический университет инноваций и непрерывного образования ФГБУ ГНЦ «Федеральный медицинский биофизический центр им. А.И. Бурназяна» Федерального медико-биологического агентства</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.I. Burnasyan Federal Medical Biophysical Center of the Federal Medical Biological Agency; Academy of Postgraduate Education of the Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of Federal Medical Biological Agency; Medico-biological University of Innovation and Continuing Education of Russian State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУ ГНЦ «Федеральный медицинский биофизический центр им. А.И. Бурназяна» Федерального медико-биологического агентства</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.I. Burnasyan Federal Medical Biophysical Center of the Federal Medical Biological Agency</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБУ ГНЦ «Федеральный медицинский биофизический центр им. А.И. Бурназяна» Федерального медико-биологического агентства; Медико-биологический университет инноваций и непрерывного образования ФГБУ ГНЦ «Федеральный медицинский биофизический центр им. А.И. Бурназяна» Федерального медико-биологического агентства</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.I. Burnasyan Federal Medical Biophysical Center of the Federal Medical Biological Agency; Medico-biological University of Innovation and Continuing Education of Russian State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>ФГБУ «Научно-исследовательский институт глазных болезней им. М.М. Краснова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of eye deseases named after M.M. Krasnov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>30</day><month>03</month><year>2025</year></pub-date><volume>22</volume><issue>1</issue><fpage>136</fpage><lpage>142</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лихванцева В.Г., Капкова С.Г., Третьяк Е.Б., Наумова В.И., Плиева Х.М., Борисенко Т.Е., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Лихванцева В.Г., Капкова С.Г., Третьяк Е.Б., Наумова В.И., Плиева Х.М., Борисенко Т.Е.</copyright-holder><copyright-holder xml:lang="en">Likhvantseva V.G., Kapkova S.G., Tretyak E.B., Naumova V.I., Plieva H.M., Borisenko T.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ophthalmojournal.com/opht/article/view/2589">https://www.ophthalmojournal.com/opht/article/view/2589</self-uri><abstract><p>Цель исследования: изучить роль персонализированных факторов риска неудовлетворительного ответа на ангиостатическую терапию на основе регрессионных моделей заболевания.Пациенты и методы. Исследование имело ретроспективный когортный дизайн, включало 84 пациента (92 глаза) с диагнозом «макулярная неоваскуляризация» (МНВ, активная форма). У 18 (19,5 %) человек процесс был двусторонним. Изучали персонализированные морфометрические показатели сетчатки и внутриглазного давления (ВГД) на глазах пациентов с МНВ, получавших интравитреальные инъекции (ИВИ) Эйлеа в фиксированном режиме, в корреляции с ответом на лечение. Ответ ранжировали на пять типов. Результаты оценивали клинически и морфометрически оптической когерентной томографией (ОКТ). Строили логистические регрессионные модели заболевания и на них изучали роль различных факторов в лечении заболевания и силу их связи с неблагоприятным исходом.Результаты. Представлены два логистических регрессионных уравнения с формулами расчета прогноза эффективности лечения ангиостатиками. Проанализирована сила связи факторов риска неблагоприятного ответа, таких как высота отслойки пигментного эпителия, наличие интраретинального отека, персонализированные показатели внутриглазного давления больного глаза, принадлежность заболевания пациента к наследственной форме ВМД, наличие вредных привычек (курение). Показано, что увеличение высоты отслойки пигментного эпителия (маркер PED_H = 170 микрон) на 1 микрон при прочих неизменных предикторах увеличивает отношение шанса отрицательного исхода к положительному на 1 %. При таком значении маркер чувствительности плохого ответа на лечение ангиостатиками составил 0,493, а специфичности — 0,737. При возникновении интраретинального отека отношение шанса отрицательного исхода к положительному увеличивалось на 68 %. В условиях повышения внутриглазного давления риск плохого ответа возрастал в 4 раза. Прогноз для курящего на 30 % хуже по сравнению с некурящим пациентом. Наследственная форма ВМД повышает риск развития плохого ответа на лечение на 25 %.Заключение. Представлена логистическая регрессионная модель заболевания, предсказывающая правильно 94 % нереспонденции, что делает прогноз достоверным, надежным и точным. Проанализированы модифицируемые (курение, PED_H &gt; 170 микрон, наличие IRF, повышение ВГД) и немодифицируемые (наследственная норма заболевания) факторы риска, имеющие важное значение в практической офтальмологии и повышающие вероятность развития неблагоприятного исхода ангиостатического лечения.</p></abstract><trans-abstract xml:lang="en"><p>Purpose: to study the role of personalized risk factors for poor response to angiostatic therapy based on a regression model of the disease.Patients and methods. The study had a retrospective cohort design, including 84 patients (92 eyes) with a newly diagnosed MNV and evidence of disease activity. In 18 (19.5 %) people, the process was bilateral. Personalized retinal morphometrics and intraocular pressure (IOP) in eyes with MNV treated with fixed intravitreal injections (IVI) of Eylea in correlation with treatment response were studied. Treatment response was ranked into five types. Treatment results were assessed clinically and morphometrically by optical coherence tomography (OCT). Based on the results of correlations, logistic regression models of the disease were built. They studied the role of various factors in the treatment of the disease and the strength of their association with an adverse outcome.Results. 2 models of the disease have been developed and presented in the form of logistic regression equations with formulas for calculating the prognosis of the effectiveness of treatment with angiostatics. The strength of the risk factors association for an adverse response was analyzed, such as the height of pigment epithelial detachment, the presence of intraretinal edema, personalized intraocular pressure indicators of the affected eye, the patient’s disease belonging to the hereditary form of AMD, the presence of bad habits (smoking). It is shown that an increase in the height of pigment epithelial detachment (marker PED_H = 170 microns) by 1 micron, with other unchanged predictors, increases the ratio of the chance of a negative outcome to a positive one by 1%. At this marker value, the sensitivity of the poor response to angiostatic treatment was 0.493 and the specificity was 0.737. When intraretinal edema occurs, the ratio of the chance of a negative outcome to a positive outcome increases by 68 %. In conditions of increased intraocular pressure, the risk of a poor response increases by 4 times. The prognosis for a smoker is 30% worse compared to a nonsmoking patient. Hereditary AMD increases the risk of developing a poor response to treatment by 25 %. Conclusion. A logistic regression model of the disease is presented, which correctly predicts 94 % of non-response, which makes the prognosis reliable, reliable and accurate. Modifiable (smoking, PED_H &gt; 170 microns, presence of IRF, increased IOP) and non-modifiable (hereditary norm of the disease) risk factors that are important in practical ophthalmology and increase the likelihood of developing an unfavorable outcome of angiostatic treatment were analyzed.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>макулярная неоваскуляризация</kwd><kwd>отслойка ретинального пигментного эпителия</kwd><kwd>антиангиогенная терапия</kwd><kwd>фактор риска</kwd><kwd>внутриглазное давление</kwd><kwd>курение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>macular neovascularization</kwd><kwd>retinal pigment epithelial abruption</kwd><kwd>antiangiogenic therapy</kwd><kwd>risk factor</kwd><kwd>intraocular pressure</kwd><kwd>smoking</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG; HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020 Jan;127(1):72–84. doi: 10.1016/j.ophtha.2019.04.017.</mixed-citation><mixed-citation xml:lang="en">Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG; HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020 Jan;127(1):72–84. doi: 10.1016/j.ophtha.2019.04.017.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Eyetech Study Group: Preclinical and phase IA clinical evalution of anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22(2):143–152. doi: 10.1097/00006982-200204000-00002.</mixed-citation><mixed-citation xml:lang="en">Eyetech Study Group: Preclinical and phase IA clinical evalution of anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22(2):143–152. doi: 10.1097/00006982-200204000-00002.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. SEVEN-UP Study Group Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292–2299. doi: 10.1016/j.ophtha.2013.03.046.</mixed-citation><mixed-citation xml:lang="en">Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. SEVEN-UP Study Group Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292–2299. doi: 10.1016/j.ophtha.2013.03.046.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenfeld PJ, Brown DM, Heier J.S. MARINA Study Group Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi: 10.1056/nejmoa054481.</mixed-citation><mixed-citation xml:lang="en">Rosenfeld PJ, Brown DM, Heier J.S. MARINA Study Group Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi: 10.1056/nejmoa054481.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Samanta A, Aziz AA. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac. J. Ophthalmol. (Phila.). 2020;9:250–259. doi: 10.1097/APO.0000000000000291.</mixed-citation><mixed-citation xml:lang="en">Samanta A, Aziz AA. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac. J. Ophthalmol. (Phila.). 2020;9:250–259. doi: 10.1097/APO.0000000000000291.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A; EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011 May;118(5):831–839. doi: 10.1016/j.ophtha.2010.09.004.</mixed-citation><mixed-citation xml:lang="en">Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A; EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011 May;118(5):831–839. doi: 10.1016/j.ophtha.2010.09.004.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Нероев ВВ, Коротких СА, Бобыкин ЕВ., Зайцева ОВ. Информационный лифлет для пациентов, получающих лечение с применением интравитреального введения лекарственных препаратов. Рекомендации Экспертного совета по заболеваниям сетчатки и зрительного нерва Общероссийской общественной организации «Ассоциация врачей-офтальмологов». Российский офтальмологический журнал. 2021;14(S2):7–19.</mixed-citation><mixed-citation xml:lang="en">Neroev VV, Short SA, Bobykin EV., Zaitseva O.V. Information leaflet for patients receiving treatment with intravitreal drug administration. Recommendations of the Expert Council on Diseases of the Retina and Optic Nerve of the All-Russian Public Organization “Association of Ophthalmologists”. Russian Ophthalmological Journal. 2021;14(S2):7–19 (In Russ). doi: 10.21516/2072-0076-2021-14-2-supplement-7-19.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Файзрахманов РР. Режимы назначения анти-VEGF-препаратов при терапии неоваскулярной возрастной макулярной дегенерации. Вестник офтальмологии. 2018;6:105–113.</mixed-citation><mixed-citation xml:lang="en">Fayzrakhmanov RR. Prescribing regimens of anti-VEGF drugs in the therapy of neovascular age-related macular degeneration. Vestnik oftal’mologii. 2018;6:105–113 (In Russ). doi: 10.21516/2072-0076-2019-12-2-97-105.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Файзрахманов РР. Анти-VEGF терапия неоваскулярной возрастной макулярной дегенерации: от рандомизированных исследований к реальной клинической практике. Российский офтальмологический журнал. 2019;12(2):97–105.</mixed-citation><mixed-citation xml:lang="en">Fayzrakhmanov RR. Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to real clinical practice. Russian Ophthalmological Journal. 2019;12(2):97–105 (In Russ). doi: 10.21516/2072-0076-2019-12-2-97-105.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Файзрахманов РР, Воропаев ВЮ, Суханова АВ, Шаталова ЕО. Антиангиогенная терапия неоваскулярной возрастной макулярной дегенерации. Вестник офтальмологии. 2021;137(1):83–93.</mixed-citation><mixed-citation xml:lang="en">Fayzrakhmanov RR, Voropaev VYu, Sukhanova AV, Shatalova EO. Antiangiogenic therapy of neovascular age-related macular degeneration. Vestnik oftal’mologii. 2021;137(1):83–93 (In Russ). doi: 10.17116/oftalma202113701183.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Brown DM, Tuomi L, Shapiro H; Pier Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. Retina. 2013 Jan;33(1):23–34. doi: 10.1097/IAE.0b013e318263cedf.</mixed-citation><mixed-citation xml:lang="en">Brown DM, Tuomi L, Shapiro H; Pier Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. Retina. 2013 Jan;33(1):23–34. doi: 10.1097/IAE.0b013e318263cedf.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Simader C, Ritter M, Bolz M, Deák GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology. 2014 Jun;121(6):1237–1245. doi: 10.1016/j.ophtha.2013.12.029.</mixed-citation><mixed-citation xml:lang="en">Simader C, Ritter M, Bolz M, Deák GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology. 2014 Jun;121(6):1237–1245. doi: 10.1016/j.ophtha.2013.12.029.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U. Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD. Ophthalmology. 2016 Jan;123(1):60–69. doi: 10.1016/j.ophtha.2015.09.013.</mixed-citation><mixed-citation xml:lang="en">Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U. Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD. Ophthalmology. 2016 Jan;123(1):60–69. doi: 10.1016/j.ophtha.2015.09.013.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bontzos G, Bagheri S, Ioanidi L, Kim I, Datseris I, Gragoudas E, Kabanarou S, Miller J, Tsilimbaris M, Vavvas DG. Nonresponders to Ranibizumab Anti-VEGF Treatment Are Actually Short-term Responders: A Prospective Spectral-Domain OCT Study. Ophthalmol Retina. 2020 Dec;4(12):1138–1145. doi: 10.1016/j.oret.2019.11.004.</mixed-citation><mixed-citation xml:lang="en">Bontzos G, Bagheri S, Ioanidi L, Kim I, Datseris I, Gragoudas E, Kabanarou S, Miller J, Tsilimbaris M, Vavvas DG. Nonresponders to Ranibizumab Anti-VEGF Treatment Are Actually Short-term Responders: A Prospective Spectral-Domain OCT Study. Ophthalmol Retina. 2020 Dec;4(12):1138–1145. doi: 10.1016/j.oret.2019.11.004.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, Harding S, Johnston RL, Kelly SP, Lotery A, Mahmood S, Menon G, Sivaprasad S, Talks J, Tufail A, Yang Y. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015 Oct;29(10):1397–1398. doi: 10.1038/eye.2015.159. Erratum for: Eye (Lond). 2015 Jun;29(6):721–731. Kelly S [corrected to Kelly SP].</mixed-citation><mixed-citation xml:lang="en">Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, Harding S, Johnston RL, Kelly SP, Lotery A, Mahmood S, Menon G, Sivaprasad S, Talks J, Tufail A, Yang Y. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015 Oct;29(10):1397–1398. doi: 10.1038/eye.2015.159. Erratum for: Eye (Lond). 2015 Jun;29(6):721–731. Kelly S [corrected to Kelly SP].</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Arnold JJ, Markey CM, Kurstjens NP, Guymer RH. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016;3:16–31. doi: 10.1186/s12886-016-0207-3.</mixed-citation><mixed-citation xml:lang="en">Arnold JJ, Markey CM, Kurstjens NP, Guymer RH. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016;3:16–31. doi: 10.1186/s12886-016-0207-3.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ashraf M, Souka A, Adelman RA. Age-related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmol. 2018;96(2):120–133.</mixed-citation><mixed-citation xml:lang="en">Ashraf M, Souka A, Adelman RA. Age-related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmol. 2018;96(2):120–133.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Pastore MR, Milan S, Cirigliano G, Tognetto D. Functional and anatomical outcomes of brolucizumab for nAMD in a real-life setting. Sci Rep. 2024;14(1):1441.</mixed-citation><mixed-citation xml:lang="en">Pastore MR, Milan S, Cirigliano G, Tognetto D. Functional and anatomical outcomes of brolucizumab for nAMD in a real-life setting. Sci Rep. 2024;14(1):1441.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Chandra S, Gurudas S, Pearce I, Mckibbin M, Kotagiri A, Menon G, Burton BJL, Talks J, Grabowska A, Ghanchi F, Gale R, Giani A, Chong V, Chen CNT, Nicholson L, Thottarath S, Chandak S, Sivaprasad S. Baseline characteristics of eyes with early residual fluid post loading phase of aflibercept therapy in neovascular AMD: PRECISE study report 3. Eye (Lond). 2024 May;38(7):1301-1307. doi: 10.1038/s41433-023-02886-1.</mixed-citation><mixed-citation xml:lang="en">Chandra S, Gurudas S, Pearce I, Mckibbin M, Kotagiri A, Menon G, Burton BJL, Talks J, Grabowska A, Ghanchi F, Gale R, Giani A, Chong V, Chen CNT, Nicholson L, Thottarath S, Chandak S, Sivaprasad S. Baseline characteristics of eyes with early residual fluid post loading phase of aflibercept therapy in neovascular AMD: PRECISE study report 3. Eye (Lond). 2024 May;38(7):1301-1307. doi: 10.1038/s41433-023-02886-1.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Зайцева ОВ, Нероева НВ, Охоцимская ТД, Бобыкин ЕВ. Анти-VEGF-терапия неоваскулярной возрастной макулярной дегенерации: причины недостаточной эффективности. Вестник офтальмологии. 2021;137(5):152–159.</mixed-citation><mixed-citation xml:lang="en">Zaitseva OV, Neroeva NV, Okhotsimskaya TD, Bobykin EV. Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration: Causes of Insufficient Efficacy. Vestnik oftal’mologii. 2021;137(5):152–159 (In Russ.). doi: 10.17116/oftalma2021137051152.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG, Souied EH, Cohen SY, Querques G, Ohno-Matsui K, Boyer D, Gaudric A, Blodi B, Baumal CR, Li X, Coscas GJ, Brucker A, Singerman L, Luthert P, Schmitz-Valckenberg S, Schmidt-Erfurth U, Grossniklaus HE, Wilson DJ, Guymer R, Yannuzzi LA, Chew EY, Csaky K, Monés JM, Pauleikhoff D, Tadayoni R, Fujimoto J. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020 May;127(5):616–636. doi: 10.1016/j.ophtha.2019.11.004.</mixed-citation><mixed-citation xml:lang="en">Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG, Souied EH, Cohen SY, Querques G, Ohno-Matsui K, Boyer D, Gaudric A, Blodi B, Baumal CR, Li X, Coscas GJ, Brucker A, Singerman L, Luthert P, Schmitz-Valckenberg S, Schmidt-Erfurth U, Grossniklaus HE, Wilson DJ, Guymer R, Yannuzzi LA, Chew EY, Csaky K, Monés JM, Pauleikhoff D, Tadayoni R, Fujimoto J. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020 May;127(5):616–636. doi: 10.1016/j.ophtha.2019.11.004.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Barış ME, Menteş J, Afrashi F. Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration. Turk J Ophthalmol. 2020;50(5):275–282. doi: 10.4274/tjo.galenos.2020.38488.</mixed-citation><mixed-citation xml:lang="en">Barış ME, Menteş J, Afrashi F. Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration. Turk J Ophthalmol. 2020;50(5):275–282. doi: 10.4274/tjo.galenos.2020.38488.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 2004;122:598–614. doi: 10.1001/archopht.122.4.598.</mixed-citation><mixed-citation xml:lang="en">Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 2004;122:598–614. doi: 10.1001/archopht.122.4.598.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
